Emergent BioSolutions, Inc. (EBS)
6.21
-0.02
(-0.32%)
USD |
NYSE |
Sep 04, 16:00
6.21
0.00 (0.00%)
Pre-Market: 20:00
Emergent BioSolutions Research and Development Expense (Quarterly) : 9.20M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.20M |
| March 31, 2026 | 10.50M |
| December 31, 2025 | 12.10M |
| September 30, 2025 | 13.50M |
| June 30, 2025 | 13.00M |
| March 31, 2025 | 15.20M |
| December 31, 2024 | 9.20M |
| September 30, 2024 | 13.20M |
| June 30, 2024 | 27.30M |
| March 31, 2024 | 15.00M |
| December 31, 2023 | 29.20M |
| September 30, 2023 | 14.40M |
| June 30, 2023 | 25.60M |
| March 31, 2023 | 43.40M |
| December 31, 2022 | 57.60M |
| September 30, 2022 | 41.60M |
| June 30, 2022 | 48.50M |
| March 31, 2022 | 45.90M |
| December 31, 2021 | 83.00M |
| September 30, 2021 | 48.70M |
| June 30, 2021 | 48.30M |
| March 31, 2021 | 51.40M |
| December 31, 2020 | 59.50M |
| September 30, 2020 | 84.40M |
| June 30, 2020 | 47.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 42.70M |
| December 31, 2019 | 62.80M |
| September 30, 2019 | 53.40M |
| June 30, 2019 | 63.90M |
| March 31, 2019 | 46.10M |
| December 31, 2018 | 52.00M |
| September 30, 2018 | 37.01M |
| June 30, 2018 | 24.74M |
| March 31, 2018 | 29.05M |
| December 31, 2017 | 28.50M |
| September 30, 2017 | 22.66M |
| June 30, 2017 | 25.75M |
| March 31, 2017 | 20.48M |
| December 31, 2016 | 27.12M |
| September 30, 2016 | 27.19M |
| June 30, 2016 | 27.89M |
| March 31, 2016 | 26.09M |
| December 31, 2015 | 25.33M |
| September 30, 2015 | 29.72M |
| June 30, 2015 | 40.94M |
| March 31, 2015 | 38.70M |
| December 31, 2014 | 38.96M |
| September 30, 2014 | 44.21M |
| June 30, 2014 | 37.40M |
| March 31, 2014 | 30.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Exelixis, Inc. | 211.99M |
| Capricor Therapeutics, Inc. | 28.57M |
| ADMA Biologics, Inc. | 6.014M |
| Akebia Therapeutics, Inc. | 13.47M |
| Arcutis Biotherapeutics, Inc. | 20.36M |